267 related articles for article (PubMed ID: 24918834)
1. Belinostat for the treatment of peripheral T-cell lymphomas.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 May; 50(5):337-45. PubMed ID: 24918834
[TBL] [Abstract][Full Text] [Related]
2. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Rashidi A; Cashen AF
Future Oncol; 2015; 11(11):1659-64. PubMed ID: 26043217
[TBL] [Abstract][Full Text] [Related]
3. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
[TBL] [Abstract][Full Text] [Related]
4. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Campbell P; Thomas CM
J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
[TBL] [Abstract][Full Text] [Related]
5. Belinostat: first global approval.
Poole RM
Drugs; 2014 Sep; 74(13):1543-54. PubMed ID: 25134672
[TBL] [Abstract][Full Text] [Related]
6. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
Lee HZ; Kwitkowski VE; Del Valle PL; Ricci MS; Saber H; Habtemariam BA; Bullock J; Bloomquist E; Li Shen Y; Chen XH; Brown J; Mehrotra N; Dorff S; Charlab R; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
Clin Cancer Res; 2015 Jun; 21(12):2666-70. PubMed ID: 25802282
[TBL] [Abstract][Full Text] [Related]
8. Belinostat: clinical applications in solid tumors and lymphoma.
Molife LR; de Bono JS
Expert Opin Investig Drugs; 2011 Dec; 20(12):1723-32. PubMed ID: 22046971
[TBL] [Abstract][Full Text] [Related]
9. Anticancer clinical efficiency and stochastic mechanisms of belinostat.
El Omari N; Bakrim S; Khalid A; Albratty M; Abdalla AN; Lee LH; Goh KW; Ming LC; Bouyahya A
Biomed Pharmacother; 2023 Sep; 165():115212. PubMed ID: 37541175
[TBL] [Abstract][Full Text] [Related]
10. Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.
Reimer P; Chawla S
J Hematol Oncol; 2013 Sep; 6():69. PubMed ID: 24020452
[TBL] [Abstract][Full Text] [Related]
11. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
Marchi E; Raufi AG; O'Connor OA
Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
[TBL] [Abstract][Full Text] [Related]
12. Development of new agents for peripheral T-cell lymphoma.
Ito Y; Makita S; Tobinai K
Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
[TBL] [Abstract][Full Text] [Related]
13. UGT genotyping in belinostat dosing.
Goey AK; Figg WD
Pharmacol Res; 2016 Mar; 105():22-7. PubMed ID: 26773202
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors: novel agents in cancer treatment.
Glass E; Viale PH
Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
[TBL] [Abstract][Full Text] [Related]
15. Beleodaq approved for rare lymphomas.
Cancer Discov; 2014 Sep; 4(9):978. PubMed ID: 25185167
[TBL] [Abstract][Full Text] [Related]
16. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor.
Gimsing P
Expert Opin Investig Drugs; 2009 Apr; 18(4):501-8. PubMed ID: 19335278
[TBL] [Abstract][Full Text] [Related]
17. Belinostat (Beleodaq) for peripheral T-Cell lymphoma.
Med Lett Drugs Ther; 2015 Apr; 57(1467):e66-7. PubMed ID: 25988963
[No Abstract] [Full Text] [Related]
18. Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer.
Finnegan E; Ding W; Ude Z; Terer S; McGivern T; Blümel AM; Kirwan G; Shao X; Genua F; Yin X; Kel A; Fattah S; Myer PA; Cryan SA; Prehn JHM; O'Connor DP; Brennan L; Yochum G; Marmion CJ; Das S
Cell Oncol (Dordr); 2024 Apr; 47(2):533-553. PubMed ID: 37934338
[TBL] [Abstract][Full Text] [Related]
19. Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology.
Shah RR
Drug Saf; 2019 Feb; 42(2):235-245. PubMed ID: 30649740
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.
Puvvada SD; Li H; Rimsza LM; Bernstein SH; Fisher RI; LeBlanc M; Schmelz M; Glinsmann-Gibson B; Miller TP; Maddox AM; Friedberg JW; Smith SM; Persky DO
Leuk Lymphoma; 2016 Oct; 57(10):2359-69. PubMed ID: 26758422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
